Cbdmd, Inc. (YCBD) Stock Forecast Oct. 13, 2026
Analysis updated on Oct. 13, 2026 (UTC) · Alpha · vs marketSwitch to Total · NYSE
Cbdmd, Inc. (YCBD) stock forecast summary
Our AI ranks Cbdmd, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
Cbdmd, Inc. is a small-cap company with a market capitalization of $4M. It ranks number 16 by market capitalization among the 16 Perfumes, Cosmetics & Other Toilet Preparations issuers in our coverage with a current forecast.
A per-ticker accuracy statistic for YCBD is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.3%, buy ≥ +0.5%, sell < -0.5%, strong sell < -1.6% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-13 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, YCBD included.
Follow YCBD freeYCBD price chart and AI forecast
How YCBD ranks among 5379 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Cbdmd, Inc. (YCBD) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Perfumes, Cosmetics & Other Toilet Preparations peers listed below that report each metric.
Valuation & Market
| Metric | YCBD | Rank |
|---|---|---|
| Market Cap | $4M | 16/16 |
| P/B Ratio | 0.49x | 11/13 |
| Book Value/Share | $0.73 | – |
| Revenue/Share | $1.87 | – |
| FCF/Share | $-0.22 | – |
Profitability & Margins
| Metric | YCBD | Rank |
|---|---|---|
| ROE | -35.2% | 12/13 |
| ROA | -22.0% | 12/16 |
| ROIC | -28.8% | 12/12 |
| Gross Margin | 57.7% | 8/14 |
| Operating Margin | -13.9% | 12/15 |
| Net Margin | -13.8% | 11/15 |
| EBT Margin | -13.8% | 12/15 |
Financial Health
| Metric | YCBD | Rank |
|---|---|---|
| Current Ratio | 2.50x | 7/16 |
| Quick Ratio | 1.37x | 7/16 |
| D/E Ratio | 0.60x | 9/14 |
| Financial Leverage | 1.60x | 11/14 |
| Interest Coverage | -345.2x | 13/13 |
| Working Capital | $5M | 11/16 |
Cash Flow
| Metric | YCBD | Rank |
|---|---|---|
| Operating Cash Flow | -$2M | 13/17 |
| Free Cash Flow | -$2M | 11/11 |
| Capital Spending | -$190K | 4/11 |
| FCF/Sales | -11.5% | 10/11 |
| CapEx/Sales | 0.9% | 8/11 |
Operational Efficiency
| Metric | YCBD | Rank |
|---|---|---|
| Asset Turnover | 1.59x | 3/14 |
| Receivables Turnover | 22.6x | 4/12 |
| Inventory Turnover | 2.6x | 8/13 |
| Fixed Assets Turnover | 62.5x | 3/13 |
| Days Sales Outstanding | 16 days | 9/12 |
| Days Inventory | 143 days | 5/13 |
| Payables Period | 61 days | 7/12 |
| Cash Conversion Cycle | 97 days | 5/11 |
Income Statement
| Metric | YCBD | Rank |
|---|---|---|
| Total Revenue | $20M | 10/14 |
| Operating Income | -$2M | 11/16 |
| Net Income | -$2M | 11/16 |
| Cost of Goods Sold | $9M | 10/15 |
Dividend & Shareholder Information
| Metric | YCBD | Rank |
|---|---|---|
| Shares Outstanding | 11M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $8M | 58.6% of assets |
| Cash & Short-term Investments | $2M | 16.1% of assets |
| Accounts Receivable | $930K | 7.1% of assets |
| Inventory | $3M | 26.4% of assets |
| Total Liabilities | $5M | 37.5% of assets |
| Short-term Debt | $2M | 12.1% of assets |
YCBD quarterly financials and insider trading
Cbdmd, Inc. (YCBD) industry peers
Companies classified under the same SEC industry code as Cbdmd, Inc. (Perfumes, Cosmetics & Other Toilet Preparations): 19 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| YCBD Cbdmd, Inc. | ▲ | $4M |
| CL Colgate Palmolive Co | ▼ | $71.71B |
| EL Estee Lauder Companies Inc | ▼ | $36.08B |
| KVUE Kenvue Inc. | ▶ | $34.11B |
| ELF E.L.F. Beauty, Inc. | ▼ | $6.38B |
| IPAR Interparfums Inc | ▼ | $3.65B |
| COTY Coty Inc. | ▲ | $2.60B |
| EPC Edgewell Personal Care Co | ▼ | $1.31B |
| WALD Waldencast Plc | ▲ | $86M |
| SLSN Solesence, Inc. | ▲ | $70M |
| SHFH Scientist Home Future Health Ltd | ▼ | $40M |
| AXIL Axil Brands, Inc. | ▶ | $40M |
| UG United Guardian Inc | ▲ | $32M |
| DQWS Dswiss Inc | ▶ | $17M |
| CABR Caring Brands, Inc. | ▲ | $14M |
| BNKK Bonk, Inc. | ▶ | $10M |
| HLN Haleon Plc | ▼ | N/A |
| KARX Karbon-X Corp. | ▼ | N/A |
| ODD Oddity Tech Ltd | ▶ | N/A |
Where YCBD sits on the market map
Cbdmd, Inc. (YCBD) stock news
Loading...
Cbdmd, Inc. (YCBD) stock forecast FAQ
What is the Cbdmd, Inc. (YCBD) stock forecast?
Our AI ranks Cbdmd, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
How accurate are Cbdmd, Inc. stock predictions?
A per-ticker accuracy statistic for YCBD is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Cbdmd, Inc. forecasts updated?
Cbdmd, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 13, 2026.
Which companies are Cbdmd, Inc.'s industry peers?
19 issuers in our coverage, YCBD included, share the SEC industry code Perfumes, Cosmetics & Other Toilet Preparations. The largest are: Colgate Palmolive Co (CL), Estee Lauder Companies Inc (EL), Kenvue Inc. (KVUE), E.L.F. Beauty, Inc. (ELF), Interparfums Inc (IPAR), Coty Inc. (COTY).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.